Exploring Biliary Tract Cancer: Top Takeaways From ASCO GI 2025 - Episode 10

Expert Perspectives in HER2-Positive BTC: Trastuzumab With Pertuzumab or Tucatinib From MyPathway and SGNTUC-019 Trials

, , ,

Panelists discuss how the MyPathway study and SGNTUC-019 basket trial demonstrated the clinical activity of trastuzumab plus pertuzumab and tucatinib, respectively, in HER2-positive biliary tract cancer (BTC), highlighting key efficacy metrics and safety profiles that inform treatment selection.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Guiding Patients Through Advanced BTC Prognosis and Expectations
    EP. 2: The Importance of Early Biomarker Testing in Managing Advanced BTC
    EP. 3: Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians
    EP. 4: Expert Insights: Challenges With ctDNA Testing in BTC
    EP. 5: Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials
    EP. 6: Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC
    EP. 7: Understanding HER2 Testing in BTC: Detection and Clinical Approaches
    EP. 8: Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC
    EP. 9: New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study
    Now Viewing
    EP. 10: Expert Perspectives in HER2-Positive BTC: Trastuzumab With Pertuzumab or Tucatinib From MyPathway and SGNTUC-019 Trials
    EP. 11: Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC
    EP. 12: Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment
    EP. 13: Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

    Video content above is prompted by the following:

    • Two other regimens for HER2-positive tumors include trastuzumab with pertuzumab or tucatinib. What were some key efficacy and safety end points from the MyPathway study and SGNTUC-019 basket trial?
    x